(DXCM) DexCom, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DXCM) DexCom, Inc. Bundle
See the Bigger Picture
This DexCom, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Dexcom G7 flagship CGM, 10-day wear
Dexcom G7 is DexCom, Inc.’s flagship and main growth engine: the 10-day CGM helped drive 2024 revenue to about $4.03 billion, up 11% year over year. In a CGM market growing at roughly mid-teens CAGR, G7’s rising adoption and strong share fit the "Star" profile: high growth, high leadership.
Stelo OTC CGM, launched in 2024
Stelo is DexCom’s first over-the-counter CGM, launched in 2024, and it fits the Stars quadrant because it opens a new adult consumer channel beyond insulin users. In DexCom’s 2025 growth story, total revenue reached about $4.0 billion, showing the scale to fund this push. The CGM market is still early, so adoption can lift volumes fast if repeat use holds.
G7 sensor consumables, recurring revenue
DexCom’s G7 is a Stars asset because each user buys a new 10-day sensor again and again, so every install keeps pulling consumables revenue. In 2024, DexCom posted $4.03 billion of revenue, and its growth still leaned on CGM use expanding across the installed base. The model is high-share and high-growth because sensor replacement drives repeat demand, not one-time device sales.
U.S. CGM franchise for type 2 and MDI users
DexCom’s U.S. CGM franchise for type 2 and MDI users is a Stars business: it taps a much bigger pool than type 1 alone, and DexCom says it serves more than 4 million users worldwide. In 2024, the Company generated about $4.0 billion in revenue, with U.S. prescription and endocrinology channels staying the core route to win new type 2 and MDI patients.
- Large pool: type 2 and MDI users.
- Strong fit in endocrinology clinics.
- Prescription channel supports scale.
International G7 rollouts, reimbursement expansion
DexCom’s international G7 rollout is a real Stars driver: the same CGM platform can scale across new countries with low product change, while payer wins expand access. FY2024 revenue was $4.03 billion, and non-U.S. expansion keeps adding runway as more health systems reimburse continuous glucose monitoring.
- Same core product, easier scale
- New launches expand addressable markets
- Payer coverage lifts adoption and repeat use
With each new reimbursement decision, DexCom can convert brand reach into share faster outside the United States.
DexCom’s G7 and Stelo Power Growth
DexCom, Inc.’s Stars are G7 and Stelo: 2024 revenue was about $4.03 billion, up 11%, and 2025 revenue was about $4.0 billion. G7 keeps growing in the high-growth CGM market, and Stelo adds a new OTC path beyond insulin users. That mix supports high share and repeat sensor demand.
| Asset | 2025/2024 | Star signal |
|---|---|---|
| G7 | $4.03B revenue | Repeat 10-day sensor sales |
| Stelo | Launched 2024 | New OTC growth channel |
What is included in the product
Detailed Word Document
DexCom’s BCG Matrix maps CGM units by growth and share, showing where to invest, hold, or divest.
Editable Excel File
Clean BCG Matrix view of DexCom’s business units to simplify portfolio decisions and spot growth vs. cash cows.
Reference Sources
Lists trusted sources behind DexCom, Inc. claims to boost credibility and support faster, better decisions.
Cash Cows
Dexcom G6 installed base
DexCom G6 is an older flagship with a large installed user base, so it still anchors recurring sensor and transmitter revenue. With DexCom reporting 2024 revenue of $4.03 billion, the G6 base sits in a more mature, slower-growth phase than G7. That mix of scale, retention, and lower growth fits a classic Cash Cow.
Dexcom Share remote monitoring platform
Dexcom Share is a mature add-on to Dexcom G7 and G6, built for caregivers and families, not for opening a new market. It monetizes the installed CGM base, so its cash flow is steady and tied to recurring sensor use.
DexCom reported 2025 revenue at about $4.0 billion, and the Share platform helps keep that base engaged by making glucose data easier to follow in real time. That makes it a cash cow in the BCG Matrix: low-growth, high-retention, and supported by existing users.
Dexcom Clarity diabetes data software
Dexcom Clarity supports glucose trend reporting and provider review for the installed CGM base, so it needs little extra sales spend. DexCom reported 2024 revenue of $4.03 billion, and Clarity helps monetize that base with low incremental cost. That makes it a steady cash cow inside the portfolio.
Dexcom Real-Time API developer platform
DexCom Real-Time API fits the Cash Cows box: it monetizes the installed CGM base through third-party digital health links, while avoiding the heavy launch cycle of new hardware. DexCom reported 2024 revenue of $4.03 billion, showing a large recurring user base that can support steadier API demand than newer product lines.
- Monetizes data, not devices.
- Uses the installed CGM ecosystem.
- Growth is steadier and more mature.
Recurring replacement sensors and transmitters from legacy users
Recurring replacement sensors and transmitters from legacy users are a cash cow because the installed base is already in place, so each refill drives repeat sales with little new customer cost. DexCom’s 2024 revenue was about $4.0 billion, and this replenishment stream helps turn that scale into cash. One user base, many repeat orders.
- Installed base drives repeat revenue
- Low acquisition cost, high share
- Replenishment supports cash flow
DexCom’s Cash Cows: Turning G6 Users Into Steady Revenue
DexCom’s Cash Cows are the mature, repeat-use layers of the CGM base: G6, Share, Clarity, and refill sensors/transmitters. DexCom reported 2025 revenue of about $4.0 billion, and these products keep turning the installed user base into steady cash with low extra selling cost.
| Cash cow | Role | 2025 data |
|---|---|---|
| G6 | Installed base | $4.0B rev |
Preview Before You Purchase
DexCom, Inc. Reference Sources
The DexCom, Inc. BCG Matrix preview you see is the exact same document you’ll receive after purchase. No sample pages, no watermarks—just the complete, ready-to-use report. Download the full file instantly and use it for analysis, presentations, or strategic planning. What you preview here is what you get.
Dogs
Dexcom G5 Mobile legacy system
DexCom G5 Mobile is an aging CGM platform, first cleared in 2015, and it has been overtaken by G6 and G7. By end-2025, it fits the Dogs bucket: low growth, limited upgrade demand, and likely shrinking revenue mix versus DexCom’s newer systems. Older hardware plus weaker pull from a 2-generation-old platform makes G5 a clear legacy SKU.
Dexcom G4 Platinum legacy platform
DexCom G4 Platinum is a prior-generation CGM and now fits the Dog profile because it no longer drives meaningful growth. DexCom's growth now comes from newer systems, while legacy hardware is largely out of the main revenue engine. In BCG terms, G4 Platinum has low market share and low growth, so it is best treated as a harvest or phase-out asset.
Dexcom SEVEN Plus legacy CGM
DexCom SEVEN Plus is a legacy CGM from DexCom, Inc.’s older product cycle, so it has little role in today’s growth markets. As a discontinued product, it fits the Dogs box: weak strategic value, no real growth, and no meaningful revenue tailwind versus newer systems like Dexcom G7.
Legacy receiver hardware
Legacy receiver hardware is a Dogs unit for DexCom, Inc.: standalone receiver-first CGM use has been displaced by smartphone-connected workflows, so demand is smaller than for current app-based systems and growth is weak. DexCom does not separately report receiver revenue, but its 2025 focus remained on connected CGM platforms, leaving legacy hardware with limited share and fading strategic value.
- Receiver-first use is being phased out.
- App-connected CGM drives current demand.
- Share is small, growth is weak.
Verily blood-based glucose monitoring collaboration
The Verily blood-based glucose monitoring collaboration has not turned into a major commercial line for DexCom, and no standalone revenue has been disclosed from it. By contrast, DexCom’s core CGM business generated about $4.0 billion in 2024 revenue, so the Verily effort has not matched the scale or momentum of the main franchise.
- 0 disclosed standalone revenue
- Not a market leader
- Far smaller than $4.0B CGM core
With no clear commercial lead and limited visible traction, the collaboration fits the BCG Dog profile: low share, weak scale, and little impact on DexCom’s growth engine.
DexCom’s Legacy Dogs Are Fading Fast
DexCom’s Dogs are legacy lines with little growth and fading share: G5 Mobile, G4 Platinum, SEVEN Plus, and receiver-first hardware. The Verily glucose project also shows weak traction, with no standalone revenue disclosed, while DexCom’s core CGM business reached about $4.0 billion in 2024, making these assets small and non-core.
| Dog asset | Status | Key signal |
|---|---|---|
| G5 Mobile | Legacy | Ousted by G6/G7 |
| G4 Platinum | Harvest | No growth |
| SEVEN Plus | Discontinued | No revenue tailwind |
| Receiver hardware | Fading | App use rising |
| Verily project | Unproven | 0 disclosed revenue |
Question Marks
Dexcom ONE
Dexcom ONE fits the Question Mark box: it targets price-sensitive markets and broader access use cases, but its share is still below DexCom’s core U.S. franchise. In DexCom, Inc.’s 2025 base, the business still leaned on the premium G7 line, so ONE’s growth runway is real, but dominance is not.
The category is attractive because CGM demand keeps widening, yet ONE still needs more scale, channel wins, and payer reach to turn that option into a Star.
Dexcom ONE+ rollout
Dexcom ONE+ is a Question Mark in DexCom, Inc.’s BCG mix: it is built for newer international markets and lower-price segments, but share is still early. DexCom posted $4.03 billion in 2024 revenue, so ONE+ sits inside a larger, well-funded push. If rollout wins payer coverage and scale, it can move toward a Star.
Prediabetes CGM use cases
Prediabetes is a huge but early CGM pool: the CDC says 97.6 million U.S. adults had prediabetes, about 1 in 3, yet CGM use is still low. DexCom can win here by pushing education, OTC-style consumer access, and simpler onboarding, but today its share in this segment is still small. That makes prediabetes a classic Question Mark: big upside, weak current penetration, and unclear near-term payoff.
Direct-to-consumer diabetes prevention
DexCom is still testing direct-to-consumer diabetes prevention, and penetration is low because CGM is mostly used through prescriptions. The U.S. has 97.6 million adults with prediabetes, so even small consumer adoption could matter, but the market is still unproven versus DexCom's about $4.03 billion 2024 revenue base.
- Large prevention pool: 97.6 million prediabetes
- Low current consumer penetration
- Fast growth if behavior change sticks
- Still a question mark, not a cash cow
Next-gen Verily-based glucose monitor
The Verily-based glucose monitor is still a future bet for DexCom, not a scaled profit engine. It could widen DexCom beyond its core CGM line, but until it shows repeatable demand and clear revenue, it fits BCG Question Mark territory. DexCom’s core business already drives the cash, so this project needs proof, not hype.
- Future growth option, not scaled yet
- Could expand beyond current CGM formats
- Needs traction before it turns into a Star
Dexcom’s Growth Bets: Big Markets, Low Share
Dexcom, Inc.’s Question Marks are ONE, ONE+, prediabetes, and future consumer glucose tools: all sit in big, growing markets, but current share is still low versus the core G7 franchise. DexCom’s $4.03 billion 2024 revenue shows the base is strong, yet these bets still need payer wins, scale, and adoption to move up the BCG grid.
| Item | Status | Key data |
|---|---|---|
| Dexcom ONE | Question Mark | Low share; price-led growth |
| Dexcom ONE+ | Question Mark | Early international rollout |
| Prediabetes | Question Mark | 97.6M U.S. adults |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.